Lineage Cell Therapeutics’ (LCTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

LCTX has been the topic of several other research reports. Maxim Group lowered their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. D. Boral Capital lowered their price objective on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday.

Lineage Cell Therapeutics Stock Performance

Shares of NYSEAMERICAN:LCTX opened at $0.65 on Tuesday. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61. The company has a market capitalization of $144.18 million, a P/E ratio of -5.45 and a beta of 1.21.

Institutional Trading of Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. HighTower Advisors LLC increased its position in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after purchasing an additional 19,100 shares during the last quarter. Fort Sheridan Advisors LLC grew its position in Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after acquiring an additional 23,000 shares in the last quarter. Red Crane Wealth Management LLC acquired a new position in Lineage Cell Therapeutics in the 4th quarter valued at about $171,000. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics in the 4th quarter valued at about $29,000. Finally, Defender Capital LLC. grew its position in Lineage Cell Therapeutics by 19.2% in the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after acquiring an additional 961,150 shares in the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.